Accumulation of Advanced Glycation End Products as a Molecular Mechanism for Aging as a Risk Factor in Osteoarthritis

Arthritis and Rheumatism

Volumn 50, Issue 4, 2004, Pages 1207-1215

  DeGroot, Jeroen ^a   Verzijl, Nicole ^a   Wenting Van Wijk, Marion J G ^b   Jacobs, Kim M G ^b   Van El, Benno ^a   Van Roermund, Peter M ^b   Bank, Ruud A ^a   Bijlsma, Johannes W J ^b   TeKoppele, Johan M ^a   Lafeber, Floris P J G ^b  

^a TNO   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; RIBOSE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; CARTILAGE; COLLAGEN DEFECT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOG; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HYPOTHESIS; IN VIVO STUDY; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL;

AGING; ANIMALS; ANTERIOR CRUCIATE LIGAMENT; CARTILAGE, ARTICULAR; CHONDROCYTES; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; OSTEOARTHRITIS; RISK FACTORS;

EID: 11144357921     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20170     Document Type: Article

References (66)

1. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635-46.
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503-8.
3. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention [review]. Arthritis Rheum 1998;41:1343-55.
4. Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999;42:17-24.
5. Muir H. The chondrocyte, architect of cartilage: biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Bioessays 1995;17:1039-48.
6. Urban JP, Maroudas A, Bayliss MT, Dillon J. Swelling pressures of proteoglycans at the concentrations found in cartilaginous tissues. Biorheology 1979;16:447-64.
7. Hardingham TE, Bayliss MT. Proteoglycans of articular cartilage: changes in aging and in joint disease. Semin Arthritis Rheum 1990;20(3 Suppl 1):12-33.
8. Freeman MA. Is collagen fatigue failure a cause of osteoarthrosis and prosthetic component migration? A hypothesis. J Orthop Res 1999;17:3-8.
9. Maroudas AI. Balance between swelling pressure and collagen tension in normal and degenerate cartilage. Nature 1976;260:808-9.
10. Bank RA, Soudry M, Maroudas A, Mizrahi J, TeKoppele JM. The increased swelling and instantaneous deformation of osteoarthritic cartilage is highly correlated with collagen degradation. Arthritis Rheum 2000;43:2202-10.
11. Lafeber FP, van Roy H, Wilbrink B, Huber-Bruning O, Bijlsma JW. Human osteoarthritic cartilage is synthetically more active but in culture less vital than normal cartilage. J Rheumatol 1992;19:123-9.
12. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998;102:2115-25.
13. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med 1995;1:1002-4.
14. Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med 1998;218:23-37.
15. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998;106:1-56.
16. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J Biol Chem 1989;264:21597-602.
17. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 1984;81:583-7.
18. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31.
19. Maroudas A, Palla G, Gilav E. Racemization of aspartic acid in human articular cartilage. Connect Tissue Res 1992;28:161-9.
20. Bank RA, Bayliss MT, Lafeber FP, Maroudas A, Tekoppele JM. Ageing and zonal variation in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic glycation affects biomechanical properties of cartilage. Biochem J 1998;330:345-51.
21. DeGroot J, Verzijl N, Bank RA, Lafeber FP, Bijlsma JW, TeKoppele JM. Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum 1999;42:1003-9.
22. Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000;350:381-7.
23. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986;314:403-8.
24. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630-4.
25. Bailey AJ, Sims TJ, Avery NC, Miles CA. Chemistry of collagen cross-links: glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 1993;296:489-96.
26. Reihsner R, Menzel EJ. Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic glycation and the inhibitory agent aminoguanidine. J Biomech 1998;31:985-93.
27. Andreassen TT, Seyer-Hansen K, Bailey AJ. Thermal stability, mechanical properties and reducible cross-links of rat tail tendon in experimental diabetes. Biochim Biophys Acta 1981;677:313-7.
28. Verzijl N, DeGroot J, Zaken CB, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002;46:114-23.
29. Tomasek JJ, Meyers SW, Basinger JB, Green DT, Shew RL. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life Sci 1994;55:855-61.
30. Chen AC, Temple MM, Ng DM, Verzijl N, DeGroot J, TeKoppele JM, et al. Induction of advanced glycation end products and alterations of the tensile properties of articular cartilage. Arthritis Rheum 2002;46:3212-7.
31. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992;267:12404-7.
32. Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci 1995;36:2358-67.
33. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395-403.
34. DeGroot J, Verzijl N, Budde M, Bijlsma JW, Lafeber FP, TeKoppele JM. Accumulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes. Exp Cell Res 2001;266:303-10.
35. Mott JD, Khalifah RG, Nagase H, Shield CF III, Hudson JK, Hudson BG. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;52:1302-12.
36. Pond MJ, Nuki G. Experimentally-induced osteoarthritis in the dog. Ann Rheum Dis 1973;32:387-8.
37. Marijnissen AC, Van Roermund PM, TeKoppele JM, Bijlsma JW, Lafeber FP. The canine groove model, compared with the ACLT model of osteoarthritis. Osteoarthritis Cartilage 2002;10:145-55.
38. Marijnissen AC, Van Roermund PM, Van Melkebeek J, Schenk W, Verbout AJ, Bijlsma JW, et al. Clinical benefit of joint distraction in the treatment of severe osteoarthritis of the ankle: proof of concept in an open prospective study and in a randomized controlled study. Arthritis Rheum 2002;46:2893-902.
39. Marijnissen AC, Van Roermund PM, Verzijl N, TeKoppele JM, Bijlsma JW, Lafeber FP. Steady progression of osteoarthritic features in the canine groove model. Osteoarthritis Cartilage 2002;10:282-9.
40. Van Valburg AA, Van Roermund PM, Marijnissen AC, Wenting MJ, Verbout AJ, Lafeber FP, et al. Joint distraction in treatment of osteoarthritis (II): effects on cartilage in a canine model. Osteoarthritis Cartilage 2000;8:1-8.
41. Lafeber FP, Vander Kraan PM, Van Roy JL, Huber-Bruning O, Bijlsma JW. Articular cartilage explant culture; an appropriate in vitro system to compare osteoarthritic and normal human cartilage. Connect Tissue Res 1993;29:287-99.
42. Bank RA, Beekman B, Verzijl N, de Roos JA, Sakkee AN, TeKoppele JM. Sensitive fluorimetric quantitation of pyridinium and pentosidine crosslinks in biological samples in a single high-performance liquid chromatographic run. J Chromatogr B Biomed Sci Appl 1997;703:37-44.
43. Bank RA, Krikken M, Beekman B, Stoop R, Maroudas A, Lafeber FP, et al. A simplified measurement of degraded collagen in tissues: application in healthy, fibrillated and osteoarthritic cartilage. Matrix Biol 1997;16:233-43.
44. Creemers LB, Jansen DC, van Veen-Reurings A, van den Bos T, Everts V. Microassay for the assessment of low levels of hydroxyproline. Biotechniques 1997;22:656-8.
45. Roosendaal G, TeKoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum 1999;42:1033-9.
46. Van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
47. DeGroot J, Verzijl N, Wenting-van Wijk MJ, Bank RA, Lafeber FP, Bijlsma JW, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001;44:2562-71.
48. Riley GP, Curry V, DeGroot J, Van El B, Verzijl N, Hazleman BL, et al. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol 2002;21:185-95.
49. Goldenberg DL, Cohen AS. Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. Medicine (Baltimore) 1978;57:239-52.
50. Pelletier JP, Martel-Pelletier J, Ghandur-Mnaymneh L, Howell DS, Woessner JF Jr. Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1985;28:554-61.
51. Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999;42:1159-67.
52. Altman RD, Tenenbaum J, Blanco LN, Howell DS. Morphological changes and swelling properties of osteoarthritic dog cartilage. Semin Arthritis Rheum 1981;11 Suppl 1:39-40.
53. Freeman MA. The pathogenesis of primary osteoarthrosis: an hypothesis. Mod Trends Orthop 1972;6:40-94.
54. Weightman BO, Freeman MA, Swanson SA. Fatigue of articular cartilage. Nature 1973;244:303-4.
55. Kempson GE. The mechanical properties of articular cartilage. In: Sokoloff L, editor. The joints and synovial fluid. New York: Academic Press; 1980. p. 177-238.
56. DeGroot J, Verzijl N, Jacobs KM, Budde M, Bank RA, Bijlsma JW, et al. Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001;9:720-6.
57. Sell DR, Lane MA, Johnson WA, Masoro EJ, Mock OB, Reiser KM, et al. Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc Natl Acad Sci U S A 1996;93:485-90.
58. Sell DR, Kleinman NR, Monnier VM. Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice. FASEB J 2000;14:145-56.
59. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Amino-guanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986;232:1629-32.
60. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A 1998;95:1301-6.
61. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, et al. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997;138:1886-92.
62. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.
63. Khaidar A, Marx M, Lubec B, Lubec G. L-arginine reduces heart collagen accumulation in the diabetic db/db mouse. Circulation 1994;90:479-83.
64. Drickamer K. Diabetes: breaking the curse of the AGEs. Nature 1996;382:211-2.
65. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275-8.
66. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000;97:2809-13.